Joint Pain Injections Market Size and Trends

The global joint pain injections market is estimated to be valued at USD 5.29 Bn in 2024 and is expected to reach USD 9.46 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031.

Joint Pain Injections Market Key Factors

To learn more about this report, request sample copy

The global joint pain injections market is driven by the growing geriatric population globally who are more prone to joint disorders. Rising awareness about non-invasive treatments is also augmenting the demand for joint injections. Furthermore, innovations in injection materials like hyaluronic acid and platelet rich plasma are expanding the treatment landscape and clinician confidence in non-surgical options. However, risks of injection such as infections and allergic reactions pose challenges to market growth.

Rise in the Obesity Rates

The increasing prevalence of obesity has become a major public health issue globally and is seen as one of the key factors contributing to the rising knee osteoarthritis disease rates. Obese and overweight populations are at a much higher risk of developing osteoarthritis of the knee as excess weight places undue pressure and stress on the knee joints over a prolonged period. For instance, as per data from World Health Organization, published on March 1, 2024, in 2022, there were 2.5 billion adults aged 18 and above who were classified as overweight, with over 890 million of them living with obesity. This accounts for 43% of adults in this age group, with the prevalence of overweight having increased since 1990, when it stood at 25%. The proportion of overweight adults varied across regions, ranging from 31% in the WHO South-East Asia region and the African region to 67% in the region of the Americas. Globally, approximately 16% of adults aged 18 and older were categorized as obese in 2022, marking a significant increase from 1990.

Increasing product approvals by regulatory authorities is expected to drive the market growth over the forecast period. For instance, in March 2021, Ono Pharmaceutical Co., Ltd., a pharmaceutical company, and SEIKAGAKU CORPORATION, a biopharmaceutical company, announced that the Ministry of Health, Labour and Welfare (MHLW) approved JOYCLU 30mg Intra-articular Injection in Japan indicated for the treatment of osteoarthritis (knee joint and hip joint).